Advances in radiation oncology · 2026
Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Shuhan, Tang Jing, Li Xin, Yin Tao, Gou ShanMiao, Wang Jing, Lin Zhenyu, Hu Jianli, Liu Hongli, Gou Xiaoxue, Wu Heshui, Zhang Tao, Xue Jun
Аннотация
PURPOSE: Optimal neoadjuvant therapy for borderline resectable pancreatic cancer/locally advanced pancreatic cancer (BRPC/LAPC) remains undefined. This study evaluated the efficacy and safety of neoadjuvant nab-paclitaxel and gemcitabine plus camrelizumab, with or without early stereotactic body radiation therapy (SBRT), among patients with BRPC/LAPC.
METHODS AND MATERIALS: This single-center, prospective trial enrolled adults with previously untreated BRPC/LAPC. Patients were assigned to an SBRT cohort, receiving early SBRT (25 Gy in 5 fractions) followed by nab-paclitaxel (125 mg/m2) plus gemcitabine (1000 mg/m2) on days 1 and 8 with camrelizumab (200 mg every 3 weeks), or to a non-SBRT cohort treated with the same chemoimmunotherapy alone. A multidisciplinary team determined whether patients underwent surgery or continued first-line therapy. The objective response rate served as the primary endpoint.
RESULTS: A total of 22 patients were enrolled (11 in each cohort). The objective response rate was 36.4% (8/22), and disease-control rate was 100% (22/22). Six patients (27.3%) underwent surgery, and all achieved clinical-to-pathologic downstaging and R0 margins (6/6). With a median follow-up of 30.0 months (95% CI, 23.3-36.7), median progression-free survival was 12.5 months (95% CI, 9.6 to not available) in the SBRT cohort and 6.6 months (95% CI, 6.4 to not available) in the non-SBRT cohort in an exploratory between-cohort analysis (P = .003). Median overall survival was 20.8 and 13.9 months in the SBRT and non-SBRT cohorts, respectively (P = .261). Toxicity profiles were similar across cohorts, with grade ≥3 treatment-related adverse events occurring in 36.4% of patients.
CONCLUSIONS: Neoadjuvant nab-paclitaxel and gemcitabine plus camrelizumab, with or without early SBRT, showed encouraging efficacy and acceptable tolerability for BRPC/LAPC. The potential benefit of early SBRT warrants further investigation.
METHODS AND MATERIALS: This single-center, prospective trial enrolled adults with previously untreated BRPC/LAPC. Patients were assigned to an SBRT cohort, receiving early SBRT (25 Gy in 5 fractions) followed by nab-paclitaxel (125 mg/m2) plus gemcitabine (1000 mg/m2) on days 1 and 8 with camrelizumab (200 mg every 3 weeks), or to a non-SBRT cohort treated with the same chemoimmunotherapy alone. A multidisciplinary team determined whether patients underwent surgery or continued first-line therapy. The objective response rate served as the primary endpoint.
RESULTS: A total of 22 patients were enrolled (11 in each cohort). The objective response rate was 36.4% (8/22), and disease-control rate was 100% (22/22). Six patients (27.3%) underwent surgery, and all achieved clinical-to-pathologic downstaging and R0 margins (6/6). With a median follow-up of 30.0 months (95% CI, 23.3-36.7), median progression-free survival was 12.5 months (95% CI, 9.6 to not available) in the SBRT cohort and 6.6 months (95% CI, 6.4 to not available) in the non-SBRT cohort in an exploratory between-cohort analysis (P = .003). Median overall survival was 20.8 and 13.9 months in the SBRT and non-SBRT cohorts, respectively (P = .261). Toxicity profiles were similar across cohorts, with grade ≥3 treatment-related adverse events occurring in 36.4% of patients.
CONCLUSIONS: Neoadjuvant nab-paclitaxel and gemcitabine plus camrelizumab, with or without early SBRT, showed encouraging efficacy and acceptable tolerability for BRPC/LAPC. The potential benefit of early SBRT warrants further investigation.